奥麦罗制药(OMER)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

OMER 奥麦罗制药

盘后交易 01-02 17:32:01 EST

16.38

-0.79

-4.63%

盘后16.59

+0.21+1.28%

17:27 EST

最高17.63	最低16.29	成交量283.05万
今开17.50	昨收17.18	日振幅7.80%
总市值11.61亿	流通市值10.57亿	总股本7,090万
成交额4,739万	换手率4.38%	流通股本6,455万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"OMER","market":"US","secType":"STK","nameCN":"奥麦罗制药","latestPrice":16.38,"timestamp":1767387600000,"preClose":17.175,"halted":0,"volume":2830483,"hourTrading":{"tag":"盘后","latestPrice":16.59,"preClose":16.38,"latestTime":"17:27 EST","volume":46450,"amount":762812.3048,"timestamp":1767392836560},"delay":0,"floatShares":64550800,"shares":70900459,"eps":-2.009792,"marketStatus":"盘后交易","change":-0.795,"latestTime":"01-02 17:32:01 EST","open":17.5,"high":17.63,"low":16.29,"amount":47392622.343916,"amplitude":0.07802,"askPrice":16.67,"askSize":677,"bidPrice":16.53,"bidSize":14,"shortable":3,"etf":0,"ttmEps":-2.009792,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1767402000000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1254974400000,"exchange":"NASDAQ","adjPreClose":17.175,"preHourTrading":{"tag":"盘前","latestPrice":17.56,"preClose":17.175,"latestTime":"09:29 EST","volume":47786,"amount":862012.275218,"timestamp":1767364171939},"postHourTrading":{"tag":"盘后","latestPrice":16.59,"preClose":16.38,"latestTime":"17:27 EST","volume":46450,"amount":762812.3048,"timestamp":1767392836560},"volumeRatio":0.319461,"impliedVol":0.9947,"impliedVolPercentile":0.476},"requestUrl":"/m/hq/s/OMER","defaultTab":"news","newsList":[{"id":"2594403267","title":"美股异动 | YARTEMLEA药物获得FDA批准 奥麦罗制药(OMER.US)暴涨近65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2594403267","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594403267?lang=zh_cn&edition=full","pubTime":"2025-12-24 23:47","pubTimestamp":1766591240,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周三，奥麦罗制药(OMER.US)暴涨近65%，创年内新高，现报14.38美元。消息面上，该公司宣布，美国食品药品监督管理局(FDA)已批准 YARTEMLEA(纳索普利单抗-wuug)用于治疗造血干细胞移植相关性血栓性微血管病(TA-TMA)，这是一种由补体凝集素途径激活引起的、通常会致命的干细胞移植并发症。YARTEMLEA 是首个也是唯一获批的凝集素通路抑制剂。YARTEMLEA 选择性抑制 MASP-2(凝集素途径的效应酶)，阻止通路激活，同时保留对宿主防御重要的经典和替代补体功能。YARTEMLEA 获批用于成人以及两岁及以上儿童。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1385701.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"美股异动 | YARTEMLEA药物获得FDA批准 奥麦罗制药(OMER.US)暴涨近65%","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4007","OMER"],"gpt_icon":0},{"id":"1175610075","title":"奥麦罗制药宣布与诺和诺德达成资产购买及许可协议，涉及其临床阶段Masp-3抑制剂Zaltenibart（Oms906）","url":"https://stock-news.laohu8.com/highlight/detail?id=1175610075","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175610075?lang=zh_cn&edition=full","pubTime":"2025-12-01 21:32","pubTimestamp":1764595946,"startTime":"0","endTime":"0","summary":"奥麦罗制药宣布与诺和诺德达成资产购买及许可协议，涉及其临床阶段Masp-3抑制剂Zaltenibart（Oms906）。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","OMER"],"gpt_icon":0},{"id":"1166722527","title":"奥麦罗制药第三季度每股收益为-0.47美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1166722527","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166722527?lang=zh_cn&edition=full","pubTime":"2025-11-20 01:45","pubTimestamp":1763574344,"startTime":"0","endTime":"0","summary":"11月13日 - 奥麦罗制药第三季度净收入为-3090万美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OMER","BK4007"],"gpt_icon":0},{"id":"2584688559","title":"奥麦罗制药盘中异动 早盘股价大涨5.07%报9.54美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2584688559","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584688559?lang=zh_cn&edition=full","pubTime":"2025-11-18 22:41","pubTimestamp":1763476860,"startTime":"0","endTime":"0","summary":"北京时间2025年11月18日22时41分，奥麦罗制药股票出现异动，股价快速上涨5.07%。截至发稿，该股报9.54美元/股，成交量28.3136万股，换手率0.40%，振幅6.50%。机构评级方面，在所有5家参与评级的机构中，60%的券商给予买入建议，40%的券商给予持有建议，无券商给予卖出建议。奥麦罗制药股票所在的生物技术行业中，整体跌幅为0.06%。narsoplimab 的临床开发目前集中在造血干细胞移植相关的血栓性微血管病和免疫球蛋白肾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251118224100a7022870&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251118224100a7022870&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","OMER"],"gpt_icon":0},{"id":"1113231586","title":"奥麦罗制药与诺和诺德达成21亿美元的药物许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1113231586","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113231586?lang=zh_cn&edition=full","pubTime":"2025-10-15 23:18","pubTimestamp":1760541535,"startTime":"0","endTime":"0","summary":"涉及临床阶段Masp-3抑制剂Zaltenibart。","market":"us","thumbnail":"https://static.tigerbbs.com/e4df472d4802ba1433868317c208391d","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/e4df472d4802ba1433868317c208391d"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"05c55ca8ae3b47a610136310aedf4cb1","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":"奥麦罗制药与诺和诺德达成21亿美元的药物许可协议","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OMER"],"gpt_icon":0},{"id":"1167744996","title":"奥麦罗制药股价翻倍，因与诺和诺德达成高达21亿美元的许可协议，最新上涨176%","url":"https://stock-news.laohu8.com/highlight/detail?id=1167744996","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167744996?lang=zh_cn&edition=full","pubTime":"2025-10-15 21:36","pubTimestamp":1760535369,"startTime":"0","endTime":"0","summary":"奥麦罗制药股价翻倍，因与诺和诺德达成高达21亿美元的许可协议，最新上涨176%","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OMER","BK4007"],"gpt_icon":0},{"id":"1169522082","title":"Novo Nordisk与奥麦罗制药达成资产购买及许可协议，涉及临床阶段的Masp-3抑制剂Zaltenibart","url":"https://stock-news.laohu8.com/highlight/detail?id=1169522082","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169522082?lang=zh_cn&edition=full","pubTime":"2025-10-15 20:30","pubTimestamp":1760531416,"startTime":"0","endTime":"0","summary":"Novo Nordisk与奥麦罗制药达成资产购买及许可协议，涉及奥麦罗制药的临床阶段Masp-3抑制剂Zaltenibart。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"05c55ca8ae3b47a610136310aedf4cb1","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OMER","BK4007"],"gpt_icon":0},{"id":"1162025811","title":"诺和诺德：根据协议条款，公司将获得在所有适应症下独占开发和商业化Zaltenibart的全球权利","url":"https://stock-news.laohu8.com/highlight/detail?id=1162025811","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162025811?lang=zh_cn&edition=full","pubTime":"2025-10-15 20:30","pubTimestamp":1760531413,"startTime":"0","endTime":"0","summary":"诺和诺德：根据协议条款，公司将获得在所有适应症下独占开发和商业化Zaltenibart的全球权利","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"05c55ca8ae3b47a610136310aedf4cb1","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OMER","BK4007"],"gpt_icon":0},{"id":"1145984759","title":"诺和诺德：奥麦罗制药有资格获得高达3.4亿美元的预付款及近期里程碑支付，总额可达21亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1145984759","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145984759?lang=zh_cn&edition=full","pubTime":"2025-10-15 20:30","pubTimestamp":1760531413,"startTime":"0","endTime":"0","summary":"诺和诺德：奥麦罗制药有资格获得高达3.4亿美元的预付款及近期里程碑支付，总额可达21亿美元","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OMER","BK4007"],"gpt_icon":0},{"id":"1120353141","title":"诺和诺德：奥麦罗制药保留与Zaltenibart无关的前临床Masp-3项目的部分权利","url":"https://stock-news.laohu8.com/highlight/detail?id=1120353141","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1120353141?lang=zh_cn&edition=full","pubTime":"2025-10-15 20:30","pubTimestamp":1760531413,"startTime":"0","endTime":"0","summary":"诺和诺德：奥麦罗制药保留与Zaltenibart无关的前临床Masp-3项目的部分权利","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OMER","BK4007"],"gpt_icon":0},{"id":"1132805269","title":"奥麦罗制药宣布发表研究成果，突出显示全球扩展准入计划中Narsoplimab治疗Ta-TMA患者的生存效果","url":"https://stock-news.laohu8.com/highlight/detail?id=1132805269","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132805269?lang=zh_cn&edition=full","pubTime":"2025-09-02 20:46","pubTimestamp":1756817208,"startTime":"0","endTime":"0","summary":"奥麦罗制药宣布发表研究成果，突出显示全球扩展准入计划中Narsoplimab治疗Ta-TMA患者的生存效果","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OMER","BK4007"],"gpt_icon":0},{"id":"2559949246","title":"奥麦罗制药盘中异动 股价大涨5.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2559949246","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2559949246?lang=zh_cn&edition=full","pubTime":"2025-08-15 21:40","pubTimestamp":1755265219,"startTime":"0","endTime":"0","summary":"北京时间2025年08月15日21时40分，奥麦罗制药股票出现异动，股价急速拉升5.46%。截至发稿，该股报4.35美元/股，成交量17.9111万股，换手率0.27%，振幅2.79%。奥麦罗制药股票所在的生物技术行业中，整体涨幅为0.32%。消息层面，截至21时40分，《奥麦罗制药将于08月14日盘后发布财报，一图速览分析师最新预测》资讯为影响奥麦罗制药的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202508152140199749e98d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202508152140199749e98d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","OMER"],"gpt_icon":0},{"id":"2558798805","title":"奥麦罗制药盘中异动 下午盘大幅上涨5.29%报3.98美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2558798805","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558798805?lang=zh_cn&edition=full","pubTime":"2025-08-09 01:19","pubTimestamp":1754673556,"startTime":"0","endTime":"0","summary":"北京时间2025年08月09日01时19分，奥麦罗制药股票出现异动，股价快速拉升5.29%。截至发稿，该股报3.98美元/股，成交量58.1847万股，换手率0.87%，振幅5.03%。机构评级方面，在所有5家参与评级的机构中，60%的券商给予买入建议，40%的券商给予持有建议，无券商给予卖出建议。奥麦罗制药股票所在的生物技术行业中，整体跌幅为0.71%。narsoplimab 的临床开发目前集中在造血干细胞移植相关的血栓性微血管病和免疫球蛋白肾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250809011917a47da9b7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250809011917a47da9b7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","OMER"],"gpt_icon":0},{"id":"2557431629","title":"奥麦罗制药盘中异动 股价大涨5.40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2557431629","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557431629?lang=zh_cn&edition=full","pubTime":"2025-08-06 02:54","pubTimestamp":1754420044,"startTime":"0","endTime":"0","summary":"北京时间2025年08月06日02时54分，奥麦罗制药股票出现波动，股价快速上涨5.40%。截至发稿，该股报3.91美元/股，成交量93.8054万股，换手率1.40%，振幅8.10%。机构评级方面，在所有5家参与评级的机构中，60%的券商给予买入建议，40%的券商给予持有建议，无券商给予卖出建议。奥麦罗制药股票所在的生物技术行业中，整体跌幅为3.38%。narsoplimab 的临床开发目前集中在造血干细胞移植相关的血栓性微血管病和免疫球蛋白肾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080602540494d1d0a6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080602540494d1d0a6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","OMER"],"gpt_icon":0},{"id":"2556375958","title":"奥麦罗制药盘中异动 股价大涨5.06%报4.05美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2556375958","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556375958?lang=zh_cn&edition=full","pubTime":"2025-08-01 00:28","pubTimestamp":1753979336,"startTime":"0","endTime":"0","summary":"北京时间2025年08月01日00时28分，奥麦罗制药股票出现异动，股价大幅上涨5.06%。截至发稿，该股报4.05美元/股，成交量46.7757万股，换手率0.70%，振幅6.10%。机构评级方面，在所有5家参与评级的机构中，60%的券商给予买入建议，40%的券商给予持有建议，无券商给予卖出建议。奥麦罗制药股票所在的生物技术行业中，整体涨幅为2.85%。narsoplimab 的临床开发目前集中在造血干细胞移植相关的血栓性微血管病和免疫球蛋白肾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080100285694c6b540&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080100285694c6b540&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["OMER","BK4007"],"gpt_icon":0},{"id":"2555068555","title":"奥麦罗制药盘中异动 股价大跌5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2555068555","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555068555?lang=zh_cn&edition=full","pubTime":"2025-07-29 23:54","pubTimestamp":1753804484,"startTime":"0","endTime":"0","summary":"北京时间2025年07月29日23时54分，奥麦罗制药股票出现异动，股价快速跳水5.06%。截至发稿，该股报3.94美元/股，成交量78.8414万股，换手率1.35%，振幅6.99%。机构评级方面，在所有5家参与评级的机构中，60%的券商给予买入建议，40%的券商给予持有建议，无券商给予卖出建议。奥麦罗制药股票所在的生物技术行业中，整体涨幅为0.36%。narsoplimab 的临床开发目前集中在造血干细胞移植相关的血栓性微血管病和免疫球蛋白肾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729235445a6c821d9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729235445a6c821d9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["OMER","BK4007"],"gpt_icon":0},{"id":"2554903772","title":"奥麦罗制药盘中异动 股价大涨7.96%报4.14美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2554903772","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554903772?lang=zh_cn&edition=full","pubTime":"2025-07-28 21:35","pubTimestamp":1753709756,"startTime":"0","endTime":"0","summary":"北京时间2025年07月28日21时35分，奥麦罗制药股票出现异动，股价快速上涨7.96%。截至发稿，该股报4.14美元/股，成交量16.7217万股，换手率0.29%，振幅5.48%。机构评级方面，在所有5家参与评级的机构中，60%的券商给予买入建议，40%的券商给予持有建议，无券商给予卖出建议。奥麦罗制药股票所在的生物技术行业中，整体涨幅为0.09%。narsoplimab 的临床开发目前集中在造血干细胞移植相关的血栓性微血管病和免疫球蛋白肾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250728213600a6c61749&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250728213600a6c61749&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","OMER"],"gpt_icon":0},{"id":"2551121349","title":"奥麦罗制药盘中异动 临近午盘股价大跌5.26%报3.42美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2551121349","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551121349?lang=zh_cn&edition=full","pubTime":"2025-07-16 23:34","pubTimestamp":1752680098,"startTime":"0","endTime":"0","summary":"北京时间2025年07月16日23时34分，奥麦罗制药股票出现波动，股价急速下挫5.26%。截至发稿，该股报3.42美元/股，成交量31.1539万股，换手率0.53%，振幅7.06%。机构评级方面，在所有5家参与评级的机构中，60%的券商给予买入建议，40%的券商给予持有建议，无券商给予卖出建议。奥麦罗制药股票所在的生物技术行业中，整体涨幅为0.96%。narsoplimab 的临床开发目前集中在造血干细胞移植相关的血栓性微血管病和免疫球蛋白肾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071623345997a89d8c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071623345997a89d8c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["OMER","BK4007"],"gpt_icon":0},{"id":"2551160876","title":"奥麦罗制药盘中异动 急速拉升5.07%报3.84美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2551160876","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551160876?lang=zh_cn&edition=full","pubTime":"2025-07-15 01:47","pubTimestamp":1752515236,"startTime":"0","endTime":"0","summary":"北京时间2025年07月15日01时47分，奥麦罗制药股票出现波动，股价急速拉升5.07%。截至发稿，该股报3.84美元/股，成交量40.7562万股，换手率0.70%，振幅5.07%。机构评级方面，在所有5家参与评级的机构中，60%的券商给予买入建议，40%的券商给予持有建议，无券商给予卖出建议。奥麦罗制药股票所在的生物技术行业中，整体涨幅为0.63%。narsoplimab 的临床开发目前集中在造血干细胞移植相关的血栓性微血管病和免疫球蛋白肾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250715014716a44a730a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250715014716a44a730a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","OMER"],"gpt_icon":0},{"id":"2550695467","title":"奥麦罗制药盘中异动 大幅拉升5.06%报3.64美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2550695467","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550695467?lang=zh_cn&edition=full","pubTime":"2025-07-11 22:04","pubTimestamp":1752242649,"startTime":"0","endTime":"0","summary":"北京时间2025年07月11日22时04分，奥麦罗制药股票出现异动，股价大幅上涨5.06%。截至发稿，该股报3.64美元/股，成交量22.4609万股，换手率0.38%，振幅5.49%。机构评级方面，在所有5家参与评级的机构中，60%的券商给予买入建议，40%的券商给予持有建议，无券商给予卖出建议。奥麦罗制药股票所在的生物技术行业中，整体跌幅为0.67%。narsoplimab 的临床开发目前集中在造血干细胞移植相关的血栓性微血管病和免疫球蛋白肾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071122041097a266d6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071122041097a266d6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["OMER","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.omeros.com","stockEarnings":[{"period":"1week","weight":0.1182},{"period":"1month","weight":0.7743},{"period":"3month","weight":3.0699},{"period":"6month","weight":4.3672},{"period":"1year","weight":0.7384},{"period":"ytd","weight":0.7384}],"compareEarnings":[{"period":"1week","weight":-0.0123},{"period":"1month","weight":0.0024},{"period":"3month","weight":0.019},{"period":"6month","weight":0.0905},{"period":"1year","weight":0.1635},{"period":"ytd","weight":0.1635}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Omeros Corporation在华盛顿成立。该公司正在推进多个开发项目，重点关注与补体系统相关的疾病和紊乱，补体系统是一组专门的蛋白质，可防止侵袭性病原体以及体内受损细胞，是人体免疫系统的重要组成部分。当触发时，补体的各种成分协同产生免疫反应，对抗感染并清除受损或死亡的细胞，维持身体系统的健康功能。然而，补体系统的失调（即过度激活或激活不足）可能是有害的，并且与感染和非感染性疾病的脆弱性增加有关，包括自身免疫性疾病、慢性炎症、血栓性微血管病和癌症。","yearOnYearQuotes":[{"month":1,"riseRate":0.375,"avgChangeRate":0.006425},{"month":2,"riseRate":0.5625,"avgChangeRate":0.058594},{"month":3,"riseRate":0.625,"avgChangeRate":0.097428},{"month":4,"riseRate":0.375,"avgChangeRate":-0.031657},{"month":5,"riseRate":0.375,"avgChangeRate":-0.032445},{"month":6,"riseRate":0.3125,"avgChangeRate":0.036171},{"month":7,"riseRate":0.4375,"avgChangeRate":0.065457},{"month":8,"riseRate":0.3125,"avgChangeRate":-0.029297},{"month":9,"riseRate":0.3125,"avgChangeRate":-0.001727},{"month":10,"riseRate":0.5,"avgChangeRate":-0.042054},{"month":11,"riseRate":0.647059,"avgChangeRate":0.236058},{"month":12,"riseRate":0.529412,"avgChangeRate":0.065706}],"exchange":"NASDAQ","name":"奥麦罗制药","nameEN":"Omeros"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"奥麦罗制药(OMER)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供奥麦罗制药(OMER)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"奥麦罗制药,OMER,奥麦罗制药股票,奥麦罗制药股票老虎,奥麦罗制药股票老虎国际,奥麦罗制药行情,奥麦罗制药股票行情,奥麦罗制药股价,奥麦罗制药股市,奥麦罗制药股票价格,奥麦罗制药股票交易,奥麦罗制药股票购买,奥麦罗制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"奥麦罗制药(OMER)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供奥麦罗制药(OMER)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}